Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Common Equity (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Common Equity for 6 consecutive years, with $107.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 26.32% to $107.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $107.5 million, a 26.32% decrease, with the full-year FY2025 number at $107.5 million, down 26.32% from a year prior.
  • Common Equity was $107.5 million for Q4 2025 at Lexicon Pharmaceuticals, down from $120.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $288.9 million in Q1 2024 to a low of $88.0 million in Q1 2023.
  • A 3-year average of $153.4 million and a median of $134.5 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 228.09% in 2024, then tumbled 57.41% in 2025.
  • Lexicon Pharmaceuticals' Common Equity stood at $93.1 million in 2023, then soared by 56.75% to $146.0 million in 2024, then fell by 26.32% to $107.5 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Common Equity are $107.5 million (Q4 2025), $120.2 million (Q3 2025), and $129.4 million (Q2 2025).